**Background**

- Trastuzumab + chemotherapy is standard treatment in 1st line advanced HER2+ gastric adenocarcinoma.
- Pembrolizumab and nivolumab approved for 3rd-line treatment of recurrent patients who are initially HER2+
- Increased affinity for activating CD32 (Fcγ II) receptor on NK cells/monocytes

**Methods**

- HER2+ (tested pre-trastuzumab), PD-L1-unselected GEA patients enrolled
- mPFS, mos. and ORR for gastric cancer pts only (n=34)

**Clinical Activity in HCC+ Gastric Cancer**

- HER2+ expressible in 28/30 patients (93.3%)
- 5 patients (17%) had undetectable HER2
- 2 patients (7%) had detectable HER2

**Conclusions**

- Margetuximab + pembrolizumab in combination is active across all Fcγ (CD16) receptor benchmarks favorably to prior experience with other agents
- Ongoing; data not reported herein

---

**References**